Deutsche Bank AG Grows Stock Holdings in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

Deutsche Bank AG boosted its position in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 16.9% in the first quarter, according to the company in its most recent filing with the SEC. The firm owned 2,589,607 shares of the company's stock after acquiring an additional 375,064 shares during the quarter. Deutsche Bank AG owned about 0.23% of Teva Pharmaceutical Industries worth $39,802,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in TEVA. Charles Schwab Investment Management Inc. lifted its holdings in shares of Teva Pharmaceutical Industries by 28.8% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 1,324,936 shares of the company's stock valued at $20,364,000 after buying an additional 296,012 shares during the period. ASR Vermogensbeheer N.V. acquired a new position in shares of Teva Pharmaceutical Industries in the 1st quarter valued at about $475,000. New Age Alpha Advisors LLC acquired a new position in Teva Pharmaceutical Industries in the 1st quarter worth about $43,000. Factorial Partners LLC raised its holdings in Teva Pharmaceutical Industries by 0.3% in the 1st quarter. Factorial Partners LLC now owns 333,000 shares of the company's stock worth $5,118,000 after purchasing an additional 1,000 shares during the period. Finally, Blair William & Co. IL raised its holdings in Teva Pharmaceutical Industries by 67.2% in the 1st quarter. Blair William & Co. IL now owns 18,782 shares of the company's stock worth $289,000 after purchasing an additional 7,550 shares during the period. Institutional investors and hedge funds own 54.05% of the company's stock.

Analyst Upgrades and Downgrades

TEVA has been the subject of a number of analyst reports. Wall Street Zen raised Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a report on Saturday, July 26th. JPMorgan Chase & Co. raised Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and upped their price target for the stock from $21.00 to $23.00 in a report on Monday, May 12th. UBS Group reduced their price target on Teva Pharmaceutical Industries from $24.00 to $23.00 and set a "buy" rating for the company in a report on Thursday, June 26th. Truist Financial initiated coverage on Teva Pharmaceutical Industries in a report on Wednesday, May 28th. They issued a "buy" rating and a $25.00 price target for the company. Finally, Hsbc Global Res raised Teva Pharmaceutical Industries to a "strong-buy" rating in a report on Monday, April 28th. Seven research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, Teva Pharmaceutical Industries presently has a consensus rating of "Buy" and a consensus price target of $24.71.

Insider Activity

In other news, insider Placid Jover sold 6,053 shares of the company's stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $15.16, for a total value of $91,763.48. Following the completion of the sale, the insider directly owned 6,774 shares in the company, valued at $102,693.84. This represents a 47.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Matthew Shields sold 6,206 shares of the company's stock in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of $17.02, for a total value of $105,626.12. Following the completion of the sale, the executive vice president owned 9,989 shares of the company's stock, valued at $170,012.78. This trade represents a 38.32% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 65,001 shares of company stock worth $996,958 over the last ninety days. Corporate insiders own 0.49% of the company's stock.

Teva Pharmaceutical Industries Price Performance

Shares of Teva Pharmaceutical Industries stock traded up $0.32 during mid-day trading on Friday, reaching $17.86. 8,344,575 shares of the stock traded hands, compared to its average volume of 12,171,490. The business has a 50-day moving average of $16.69 and a 200 day moving average of $16.29. Teva Pharmaceutical Industries Ltd. has a fifty-two week low of $12.47 and a fifty-two week high of $22.80. The stock has a market capitalization of $20.48 billion, a PE ratio of -111.63, a PEG ratio of 1.02 and a beta of 0.62. The company has a quick ratio of 0.77, a current ratio of 1.06 and a debt-to-equity ratio of 2.45.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last announced its earnings results on Wednesday, July 30th. The company reported $0.66 EPS for the quarter, beating analysts' consensus estimates of $0.64 by $0.02. Teva Pharmaceutical Industries had a positive return on equity of 46.10% and a negative net margin of 0.95%. The business had revenue of $4.18 billion during the quarter, compared to analysts' expectations of $4.34 billion. During the same quarter in the prior year, the firm earned $0.61 earnings per share. The business's revenue was up .3% compared to the same quarter last year. On average, analysts predict that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.